{"url_path":"/sec/dmra/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-219327-index.html","accession_number":"0001193125-26-219327","cik":"0001800315","ticker":"DMRA","issuer_name":"Damora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-219327-index.html","primary_entity_key":"0001800315","primary_entity_name":"Damora Therapeutics, Inc."},"word_count":62,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n \n\nRule 10b5-1 Trading Plans\n\nDuring the three months ended March 31, 2026, none of the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.\n\n \n\n \n\n67\n\n \n\n \n\n68"}